Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDE8B | O95263 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28483278 | 0.96 | ATM (0.51) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL18849728 | 0.96 | ATM (0.50) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2687739 | 0.94 | ATM (0.50) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20828130 | 0.91 | ATM (0.60) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20828126 | 0.91 | ATM (0.60) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2687901 | 0.91 | ATM (0.60) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL29036991 | 0.90 | ATM (0.48) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3422188 | 0.89 | ATM (0.47) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL29551106 | 0.89 | ATM (0.47) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL29550329 | 0.89 | ATM (0.47) | ATMALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922388-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-8168657-B2 | administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient | BOWEN J PHILLIP (US) | 2012-05-01 | — | — | US | disclosed |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | BOWEN J PHILLIP (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2003061598-A2 | SOLENOPSIN A, B AND ANALOGS AS NOVEL ANGIOGENESIS INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | VEGFA, TEK, FLT1 | ATM 3280/4885ALDH1A1 1111/4885MEN1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.